Skip To Main Content
M Mwamburi on Muck Rack

M Mwamburi

As seen in: Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to M Mwamburi’s profile

Articles by M Mwamburi

|
By M Nanavaty, S Gala, A Nyandege, M Mwamburi
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By M Nanavaty, A Nyandege, S Gala, M Mwamburi
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By M Nanavaty, S Gala, A Nyandege, M Mwamburi
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By A Shah, S Gala, M Nanavaty, S Narayanan, M Mwamburi
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By M Mwamburi, M Nanavaty, S Gala, A Nyandege
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By S Gala, A Shah, M Mwamburi
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By M Mwamburi, S Gala, M Nanavaty, A Nyandege, V Ramesh
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By V Ramesh, S Shah, S Kochel, M Mwamburi, S Narayanan
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
|
By M Mwamburi, S Gala, H Dalal
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?

PCSK9 Inhibitors - Alirocumab and Evolucumab: Key Insights on Differentiation in a Generic Market

|
By M Mwamburi, S Kochel
| Value in Health Journal Verified
Generic statins are the standard of care for 3 million Americans affected annually by dyslipidemia. Approximately 20% of these individuals are intolerant, and PCSK9 inhibitors provide an effective alternative. Recent drug launches (such as sofosbuvirir) have raised Payer scrutiny regarding drug pricing, triggering proactive review of therapies, such as PCSK9 inhibitors, which could pose considerable budget impact.
Open in Who Shared Issue with article?

Assessment and Characterization of Gaps in Literature of Resource Utilization and Economic Burden in Inflammatory Myopathies

|
By S Gala, M Mwamburi
| Value in Health Journal Verified
Inflammatory myopathies (IM) including polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM) pose a significant burden on patients and payers. These rare diseases have no approved treatments or clinical guidelines, however their cost burden equals or exceeds that of rheumatoid arthritis and systemic sclerosis. There are significant knowledge gaps on resource utilization and cost burden in IM.
Open in Who Shared Issue with article?

Indirect Treatment Comparison Of Newer Treatments In Relapsed / Refractory Multiple Myeloma

|
By S Gala, M Mwamburi
| Value in Health Journal Verified
Relapsed / refractory multiple myeloma (rrMM) remains challenging to treat effectively. Results of two major phase III randomized controlled trials (RCTs), ASPIRE for carfilzomib and ELOQUENT-2 for elotuzumab, both in combination with lenalidomide and dexamethasone (CLD and ELD respectively) in rrMM were compared to placebo plus lenalidomide and dexamethasone (LD). We performed an indirect treatment comparison (ITC) to compare CLD versus ELD.
Open in Who Shared Issue with article?
Show More